PUBLIC COMPANY
save$IKTInhibikase Therapeutics, Inc.
$IKT2.3900-0.83%Wilmington, DE, USupdated 12h ago
community read0 votes
pipeline
2
marketed
0
phase 3
1
catalysts ytd
5
approvals ytd
2
recalls ytd
0
Pipeline(2)
pipeline depth2 products
1Phase 21Phase 3
Upcoming
no upcoming catalysts on record
Recent(90d)
earnings (1)
Active trials
- phase3Open-Label Study of IKT-001 in Pulmonary Arterial Hypertension (PAH)
- phase3An Adaptive Program of IKT-001 in Pulmonary Arterial Hypertension (PAH)
- phase1A Dose Calibration Study Comparing IkT-001Pro to Imatinib Mesylate 400mg
- phase2A Phase 2 Study of IkT-001Pro in Pulmonary Arterial Hypertension (PAH)
Insider activity
source: SEC Form 4routine RSU / option mechanics (3)
- Feb 21, 26dispo to issuerAurentz Vincent · director255,299 sh
- Feb 21, 26dispo to issuerCabell Christopher · President & Head of R&D338,282 sh
- Feb 21, 26dispo to issuerMunshi Amit · director19,089 sh
🐶 Hiring Signal
News
no news has mentioned this company yet
Data sources
last refreshed 4m ago
Found something off?
comments(0)
5-min edit window · permanent after that